You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Molecular Monitoring

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma Trial in Philadelphia (Nivolumab, IV, 240 mg)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • Nivolumab, IV, 240 mg
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jan 3, 2023

NSCLC, IMMUNOTHERAPY, QUANTIFICATION OF CELL-FREE DNA Trial in France (Molecular monitoring by quantification of cell-free DNA)

Recruiting
  • NSCLC
  • +2 more
  • Molecular monitoring by quantification of cell-free DNA
  • Besançon, France
  • +7 more
Nov 18, 2022

Extramedullary Myeloma Trial in Melbourne (Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent)

Not yet recruiting
  • Extramedullary Myeloma
  • Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Dec 18, 2022

Pancreatic Cancer, Advanced Cancer, Metastatic Cancer Trial in Beijing (Later-line therapy)

Recruiting
  • Pancreatic Cancer
  • +2 more
  • Later-line therapy
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Apr 10, 2023

Next-Generation-Sequencing Trial (Molecular genetic diagnostic)

Not yet recruiting
  • Next-Generation-Sequencing
  • Molecular genetic diagnostic
  • (no location specified)
May 12, 2023

Pancreatic Cancer, Resectable Carcinoma Trial in Beijing (Later-line therapy)

Recruiting
  • Pancreatic Cancer
  • Resectable Carcinoma
  • Later-line therapy
  • Beijing, China
    Department of Medical Oncology, Peking Union Medical College Hos
Apr 10, 2023

Pancreatic Cancer, Locally Advanced Trial in Beijing (Later-line therapy)

Recruiting
  • Pancreatic Cancer
  • Locally Advanced
  • Later-line therapy
  • Beijing, China
    Department of Medical Oncology, Peking Union Medical College Hos
Apr 10, 2023

Molecular Phenotyping of Post-COVID With Focus on Lung

Recruiting
  • Long COVID
    • Stockholm, Sverige, Sweden
      Karolinska Institutet/Karolinska University Hospital Solna
    Jun 7, 2023

    Venous Thromboembolism Trial (Peak value anti-Xa, Trough value anti-Xa, Control Group)

    Not yet recruiting
    • Venous Thromboembolism
    • Peak value anti-Xa
    • +2 more
    • (no location specified)
    May 15, 2022

    Therapy After Kidney Transplantation

    Recruiting
    • Transplantation Infection
    • Kidney Diseases
      • Odense, DK, Denmark
        Odense University Hospital
      Nov 5, 2021

      Circulating Tumor DNA in Surgical Patients With Lung Cancer

      Active, not recruiting
      • Lung Cancer
        • Chengdu, Sichuan, China
          West China Hospital, Sichuan University
        Oct 12, 2022

        Ponatinib in CML Patients in Chronic Phase

        Recruiting
        • Chronic Myeloid Leukemia, Chronic Phase
        • Therapeutic drug monitoring
        • Molecular Response
        • Cagliari, Italy
        • +4 more
        Nov 3, 2023

        Is Anti-Factor Xa Associated With Outcome in Critical COVID-19

        Completed
        • Covid19
        • +2 more
        • The effect of LMWH
        • Monitoring frequency of aFXa-levels
        • Stockholm, Sweden
          Södersjukhuset
        Feb 24, 2022

        Chronic Myeloid Leukemia Trial in New York (Nilotinib)

        Completed
        Has Results
        • Chronic Myeloid Leukemia
        • New York, New York
          Weill Cornell Medical College
        Mar 24, 2022

        MRD Monitoring in Lung Cancer After Resection

        Recruiting
        • Lung Cancer
        • MRD detection
        • Guangzhou, Guangdong, China
          Guangdong Lung Cancer Institute & Guangdong Provincial People's
        Mar 2, 2022

        IDH2 Mutations and Monitoring Molecular Residual Disease in AML

        Enrolling by invitation
        • Acute Myeloid Leukemia
          • Taoyuan, State, Taiwan
            Chang Gung Memorial Hospital-Linkou
          Aug 4, 2021

          DLBCL, DLBCL Germinal Center B-Cell Type, DLBCL, Not Otherwise Specified Trial in Columbus (Molecular Nanotechnology)

          Recruiting
          • Diffuse Large B-Cell Lymphoma
          • +3 more
          • Molecular Nanotechnology
          • Columbus, Ohio
            Ohio State University Comprehensive Cancer Center
          Jun 2, 2022

          Significance of MRD After Surgery in Driver Gene-positive and

          Enrolling by invitation
          • NSCLC MRD ctDNA
            • Shenzhen, China
              ShenzhenPH
            Jun 30, 2022

            Human African Trypanosomiasis, Sleeping Sickness, Trypanosoma Brucei Gambiense; Infection Trial in Bobo Dioulasso, Kinshasa,

            Completed
            • Human African Trypanosomiasis
            • +5 more
            • Rapid diagnostic test (RDT); Serological and molecular tests on DBS
            • Bobo Dioulasso, Burkina Faso
            • +2 more
            Apr 14, 2022

            Metastatic Renal Cell Carcinoma Trial in Shanghai (sunitinib or pazopanib, PD-1 inhibitor combined with axitinib)

            Recruiting
            • Metastatic Renal Cell Carcinoma
            • sunitinib or pazopanib
            • PD-1 inhibitor combined with axitinib
            • Shanghai, Shanghai, China
              Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
            Apr 16, 2023

            Prebiotics Trial in Stanford (Dietary fiber supplementation)

            Completed
            • Prebiotics
            • Dietary fiber supplementation
            • Stanford, California
              Stanford University
            Jan 9, 2021

            Artemisinin Resistance Through Repeated Cross-sectional

            Completed
            • Severe Malaria
            • Blood sample (combined with malaria RDT) followed by gentoyping analysis
            • Kenge, Kwango, Congo, The Democratic Republic of the
            • +6 more
            Jan 28, 2021

            Molecular Biosensors for Detection of Bladder Cancer

            Recruiting
            • Urinary Bladder Neoplasms
              • Orange, California
                University of California Irvine
              Apr 1, 2021

              CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

              Recruiting
              • CML
              • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
              • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
                FUNDALEU
              Jun 29, 2023

              New Treatment Strategies in Eastern European Region and in

              Recruiting
              • HIV-1-infection
                • Cologne, Germany
                • +3 more
                Nov 10, 2023